We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp
NYMX

Delisted

NYMX was delisted on the 6th of July, 2023.

Back to rankings

58 hedge funds and large institutions have $14.2M invested in Nymox Pharmaceutical Corp in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

1% more capital invested

Capital invested by funds: $14M → $14.2M (+$193K)

9% less funds holding

Funds holding: 64 → 58 (-6)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

68% less call options, than puts

Call options by funds: $27K | Put options by funds: $84K

Holders
58
Holders Change
-6
Holders Change %
-9.38%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
21
Reduced
14
Closed
10
Calls
$27K
Puts
$84K
Net Calls
-$57K
Net Calls Change
-$13K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$241K
2
JP Morgan Chase
JP Morgan Chase
New York
+$192K
3
Renaissance Technologies
Renaissance Technologies
New York
+$70K
4
Morgan Stanley
Morgan Stanley
New York
+$61K
5
Invesco
Invesco
Georgia
+$60.2K

Top Sellers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
-$250K
2
TRCT
Tower Research Capital (TRC)
New York
-$150K
3
Jane Street
Jane Street
New York
-$106K
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$104K
5
HAG
HighPoint Advisor Group
Illinois
-$73K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$82K +$21.4K +9,663 +42%
PAG
27
Private Advisor Group
New Jersey
$77K – – –
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$75K +$8.47K +3,833 +14%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$71K -$2.97K -1,346 -4%
BAS
30
Brown Advisory Securities
Maryland
$69K – – –
Invesco
31
Invesco
Georgia
$68K +$60.2K +27,249 New
TRCT
32
Tower Research Capital (TRC)
New York
$64K -$150K -67,756 -73%
Goldman Sachs
33
Goldman Sachs
New York
$63K +$4.11K +1,858 +8%
GG
34
Gofen & Glossberg
Illinois
$62K – – –
WCWM
35
Willow Creek Wealth Management
California
$60K – – –
Russell Investments Group
36
Russell Investments Group
United Kingdom
$54K -$104K -47,056 -68%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$54K +$15.7K +7,125 +49%
Brown Advisory
38
Brown Advisory
Maryland
$46K – – –
Credit Agricole
39
Credit Agricole
France
$45K – – –
Creative Planning
40
Creative Planning
Kansas
$44K – – –
Barclays
41
Barclays
United Kingdom
$34K -$11.7K -5,278 -28%
Squarepoint
42
Squarepoint
New York
$29K -$13.9K -6,299 -35%
KAS
43
Kestra Advisory Services
Texas
$29K – – –
CAM
44
Cubic Asset Management
Massachusetts
$28K +$1.66K +750 +7%
UBS Group
45
UBS Group
Switzerland
$28K +$21.9K +9,898 +615%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$19K +$950 +430 +6%
Citigroup
47
Citigroup
New York
$19K +$12.4K +5,613 +280%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$15.9K -$5.93K -2,683 -30%
Legal & General Group
49
Legal & General Group
United Kingdom
$12K – – –
Osaic Holdings
50
Osaic Holdings
Arizona
$10K -$1.77K -800 -16%
1
2
3

NYMX Hedge Fund Activity: Q4 2020 in Review

58 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2020, worth a combined $14.2M — up 1.4% from $14M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NYMX and 4 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 21 added.

The largest buyer was State Street, adding an estimated $241K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $250K sold.

  • 58 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2020, down from 64 in Q3 2020.
  • Funds reported $14.2M of Nymox Pharmaceutical Corp stock for Q4 2020, up 1.4% quarter-over-quarter.
  • 4 funds opened new Nymox Pharmaceutical Corp positions in Q4 2020 and 10 closed out, a net change of -6 holders.
  • The largest Nymox Pharmaceutical Corp buyer in Q4 2020 was State Street, an estimated $241K added.
  • The largest Nymox Pharmaceutical Corp seller in Q4 2020 was Worth Venture Partners, an estimated $250K sold.

Based on aggregated 13F filings for Q4 2020.